HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): William D. Hoffman Jennifer Walker David Torchiana Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Everett, B. M. Articles by Jang, I.-K. Search for Related Content PubMed PubMed Citation Articles by Everett, B. M. Articles by Jang, I.-K. Related Collections Cardiac - pharmacology Extracorporeal circulation

Ann Thorac Surg 2007;83:592-597
© 2007 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery

^a Department of Medicine, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^b Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^c Department of Anesthesia and Critical Care, Cardiac Anesthesia Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^d Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Accepted for publication September 11, 2006.

^_* Address correspondence to Dr Jang, Cardiology Division, Gray/Bigelow 800, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 (Email: ijang{at}partners.org).

BACKGROUND: The clinical significance of heparin/platelet factor 4 (PF4) antibodies in subjects undergoing cardiac surgery has not been systematically studied. We prospectively investigated whether the presence of heparin/PF4 antibodies would predict clinical thrombosis in this population.

METHODS: In 299 patients scheduled for cardiac surgery between October 2003 and March 2005, the heparin/PF4 antibodies and platelet count were measured immediately prior to, and 5 days after, surgery. The patients were followed up at 30 days for thrombotic complications.

RESULTS: The prevalence of the heparin/PF4 antibodies was 4.3% (13 of 299) prior to surgery and increased more than fivefold to 22.4% (62 of 277) postoperatively (p < 0.0001). Thromboembolic events occurred in 8.8% of patients with negative antibody and in 6.3% of patients with positive antibody (p = 0.77). Of the 62 patients with positive heparin/PF4 antibodies postoperatively, 22 (35.5%) were treated with a nonheparin anticoagulant. There was a trend toward higher rates of thromboembolic events in subjects who were thrombocytopenic compared with those who were not (17.1% and 6.7%, respectively, p = 0.06), regardless of antibody status. Two out of 8 patients (25%) with both thrombocytopenia and a positive antibody (clinical heparin-induced thrombocytopenia [HIT]) suffered a thromboembolic event, compared with 17 of 222 (7.7%) without clinical HIT (p = 0.13).

CONCLUSIONS: The high prevalence of antibodies to the heparin/PF4 complex after cardiac surgery and the low rate of thromboembolic complications in this population suggest that the antibody alone does not confer an increased risk of thrombotic complications. Monitoring for thrombocytopenia is recommended.

This article has been cited by other articles:

				T. L. Ortel Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation Hematology, January 1, 2009; 2009(1): 225 - 232. [Abstract] [Full Text] [PDF]

				D. Paparella, G. Scrascia, A. Galeone, M. Coviello, G. Cappabianca, M. T. Venneri, B. Favoino, M. Quaranta, L. de Luca Tupputi Schinosa, and T. E. Warkentin Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1456 - 1463. [Abstract] [Full Text] [PDF]

				A. Greinacher and J. H. Levy HIT Happens: Diagnosing and Evaluating the Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., August 1, 2008; 107(2): 356 - 358. [Full Text] [PDF]

				K. Knobloch, A. Gohritz, M. Spies, and P. M. Vogt HIT in OPCAB surgery Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 382 - 382. [Full Text] [PDF]

				L. E. Samuels, J. Kohout, E. Casanova-Ghosh, K. Hagan, P. Garwood, F. Ferdinand, and S. M. Goldman Argatroban as a Primary or Secondary Postoperative Anticoagulant in Patients Implanted With Ventricular Assist Devices Ann. Thorac. Surg., May 1, 2008; 85(5): 1651 - 1655. [Abstract] [Full Text] [PDF]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]